MCK
55
-4
VNO
56
-3
PLD
46
-4
QCOM
51
-5
UPS
55
4
BLK
67
4
DE
56
-2
KHC
18
-2
SEE
53
-2
KR
56
11
TGNA
56
2
CINF
29
-5
NVDA
51
-3
EMC
71
-6
SWKS
48
-2
CCL
70
2
EXR
53
-2
BA
63
5
LYB
39
2
VRSK
66
3
MCK
55
-4
VNO
56
-3
PLD
46
-4
QCOM
51
-5
UPS
55
4
BLK
67
4
DE
56
-2
KHC
18
-2
SEE
53
-2
KR
56
11
TGNA
56
2
CINF
29
-5
NVDA
51
-3
EMC
71
-6
SWKS
48
-2
CCL
70
2
EXR
53
-2
BA
63
5
LYB
39
2
VRSK
66
3
Financhill
Back

Hansa Biopharma AB 10K Form

Sell
39

HNSBF
Hansa Biopharma AB

Last Price:
2.83
Seasonality Move:
-0.32%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive HNSBF News And Ratings

See the #1 stock for the next 7 days that we like better than HNSBF

HNSBF Financial Statistics

Sales & Book Value

Annual Sales: $12.67M
Cash Flow: $-15.33M
Price / Cash Flow: 0
Annual Sales: $-0.48
Price / Book: 0

Profitability

EPS (TTM): -1.07900
Net Income (TTM): $-62.29M
Gross Margin: $6.7M
Return on Equity: 0%
Return on Assets: -65.34%

Hansa Biopharma AB Earnings Forecast

Key Hansa Biopharma AB Financial Ratios

  • The Gross Profit Margin over the past 16 years for HNSBF is 52.91%.
  • The Selling, General & Administrative Expenses for HNSBF have been equal to 335.95% of Gross Profit Margin.
  • The Research & Development expenses have been 306.75% of Revenue.
  • The Interest Expense is -12.69% of Operating Income.
  • The Net Earning history of HNSBF is -620.25% of Total Revenues.
  • Per Share Earnings over the last 16 years have been positive in 4 years.

Hansa Biopharma AB Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Biotechnology
Sector: Health Care
Current Symbol: HNSBF
Website: hansabiopharma.com

Debt

Debt-to-Equity Ratio: -2.95
Current Ratio: 2.45
Quick Ratio: 2.44

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

HNSBF Technical Analysis vs Fundamental Analysis

Sell
39
Hansa Biopharma AB (HNSBF) is a Sell

Is Hansa Biopharma AB a Buy or a Sell?